EP3347012A4 - Muskarinische kombinationen und deren verwendung zur bekämpfung hypocholinergischer störungen des zentralen nervensystems - Google Patents
Muskarinische kombinationen und deren verwendung zur bekämpfung hypocholinergischer störungen des zentralen nervensystems Download PDFInfo
- Publication number
- EP3347012A4 EP3347012A4 EP16845102.9A EP16845102A EP3347012A4 EP 3347012 A4 EP3347012 A4 EP 3347012A4 EP 16845102 A EP16845102 A EP 16845102A EP 3347012 A4 EP3347012 A4 EP 3347012A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- muscarinic
- combinations
- controlling
- nervous system
- central nervous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562217081P | 2015-09-11 | 2015-09-11 | |
| US201662351382P | 2016-06-17 | 2016-06-17 | |
| PCT/US2016/050907 WO2017044714A1 (en) | 2015-09-11 | 2016-09-09 | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3347012A1 EP3347012A1 (de) | 2018-07-18 |
| EP3347012A4 true EP3347012A4 (de) | 2019-04-17 |
Family
ID=58240063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP16845102.9A Withdrawn EP3347012A4 (de) | 2015-09-11 | 2016-09-09 | Muskarinische kombinationen und deren verwendung zur bekämpfung hypocholinergischer störungen des zentralen nervensystems |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3347012A4 (de) |
| CA (1) | CA2996719A1 (de) |
| WO (1) | WO2017044714A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3061821B1 (de) | 2009-07-22 | 2019-07-10 | Puretech Health LLC | Zusammensetzungen zur behandlung von durch muscarinrezeptoraktivierung gelinderten leiden |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| IL281809B (en) | 2018-09-28 | 2022-09-01 | Karuna Therapeutics Inc | Compositions and methods for the treatment of diseases improved by the activation of muscarinic receptors |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016144749A1 (en) * | 2015-03-06 | 2016-09-15 | Chase Thomas N | Oxybutynin-xanomeline transdermal therapeutic system combinations |
| WO2016144719A1 (en) * | 2015-03-06 | 2016-09-15 | Chase Thomas N | Oxybutynin transdermal therapeutic system muscarinic agonist combination |
| WO2017015349A1 (en) * | 2015-07-20 | 2017-01-26 | Chase Pharmaceuticals Corporation | Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders |
| WO2017044693A1 (en) * | 2015-09-11 | 2017-03-16 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
| WO2017147104A1 (en) * | 2016-02-24 | 2017-08-31 | Chase Pharmaceuticals Corporation | Muscarinic m2-antagonist combinations |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030124176A1 (en) * | 1999-12-16 | 2003-07-03 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
| US20130289019A1 (en) * | 2012-04-26 | 2013-10-31 | Amazing Grace, Inc. | Methods of treating behaviorial and/or mental disorders |
| KR20200065113A (ko) * | 2012-09-05 | 2020-06-08 | 체이스 파마슈티칼스 코포레이션 | 항콜린 신경보호 조성물 및 그 방법 |
-
2016
- 2016-09-09 EP EP16845102.9A patent/EP3347012A4/de not_active Withdrawn
- 2016-09-09 CA CA2996719A patent/CA2996719A1/en active Pending
- 2016-09-09 WO PCT/US2016/050907 patent/WO2017044714A1/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016144749A1 (en) * | 2015-03-06 | 2016-09-15 | Chase Thomas N | Oxybutynin-xanomeline transdermal therapeutic system combinations |
| WO2016144719A1 (en) * | 2015-03-06 | 2016-09-15 | Chase Thomas N | Oxybutynin transdermal therapeutic system muscarinic agonist combination |
| WO2017015349A1 (en) * | 2015-07-20 | 2017-01-26 | Chase Pharmaceuticals Corporation | Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders |
| WO2017044693A1 (en) * | 2015-09-11 | 2017-03-16 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
| WO2017147104A1 (en) * | 2016-02-24 | 2017-08-31 | Chase Pharmaceuticals Corporation | Muscarinic m2-antagonist combinations |
Non-Patent Citations (2)
| Title |
|---|
| See also references of WO2017044714A1 * |
| SRAMEK J J ET AL: "THE SAFETY AND TOLERANCE OF XANOMELINE TARTRATE IN PATIENTS WITH ALZHEIMER'S DISEASE", JOURNAL OF CLINICAL PHARMACOLOGY, LIPPINCOTT CO, HAGERSTOWN, MD, US, vol. 35, 1 January 1995 (1995-01-01), pages 800 - 806, XP000563129, ISSN: 0091-2700 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2996719A1 (en) | 2017-03-16 |
| WO2017044714A1 (en) | 2017-03-16 |
| EP3347012A1 (de) | 2018-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279931A (en) | Gene therapies for lysosomal disorders | |
| EP3692075A4 (de) | Gentherapien für lysosomale erkrankungen | |
| EP3364993A4 (de) | Verfahren zur behandlung des angelman-syndroms und verwandter störungen | |
| EP3692151A4 (de) | Gentherapien für lyosomale erkrankungen | |
| IL266692A (en) | Methods and systems for predicting DNA accessibility in a cancer genome | |
| EP3104708A4 (de) | Regenerative zelltherapie für erkrankungen des zentralen nervensystems (zns) und ptsd | |
| EP3551052A4 (de) | Verfahren und systeme zur identifizierung von hirnerkrankungen | |
| HRP20210518T1 (hr) | Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava | |
| MA51074A (fr) | Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine | |
| ZA201806382B (en) | Liquid filter arrangement and methods | |
| EP2807412A4 (de) | Nervenüberwachungsverfahren und systeme zur behandlung von erkrankungen des rachens | |
| HUE051488T2 (hu) | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére | |
| FR2997317B1 (fr) | Adsorbant de tamis moleculaire de 5 a et procede pour la preparation de celui-ci | |
| EP3162567A4 (de) | Kanalelement, flüssigkeitsausstosskopf und aufzeichnungsvorrichtung | |
| EP3442547A4 (de) | Probiotische therapien für entwicklungsstörungen und andere neurologische erkrankungen | |
| EP3618824A4 (de) | Verwendung von n-acetylcystein zur behandlung von erkrankungen des zentralen nervensystems | |
| IL233141B (en) | A pharmaceutical preparation for the treatment of hearing and balance disorders | |
| EP2934565A4 (de) | Ghrh-agonisten zur behandlung von ischämischen erkrankungen | |
| EP3199353A4 (de) | Flüssigkeitsausstosskopf und aufzeichnungsvorrichtung | |
| HUE057479T2 (hu) | Szûrõkészülék elválasztólappal | |
| EP3318408A4 (de) | Flüssigkeitsentladungskopf und aufzeichnungsvorrichtung mit verwendung davon | |
| EP3463417A4 (de) | Kombinationstherapien zur regeneration/zum austausch von sensorischem haarzellen im innenohr | |
| EP2893014A4 (de) | Transponierbare elemente, tdp-43 und neurodegenerative erkrankungen | |
| EP3347011A4 (de) | Muscarinkombination und deren verwendung zur bekämpfung von hypocholinergen störungen des zentralen nervensystems | |
| EP3395581A4 (de) | Flüssigkeitsausstossvorrichtung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20180404 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031435000 Ipc: A61K0031216000 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20190318 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/454 20060101ALI20190312BHEP Ipc: A61K 45/06 20060101ALI20190312BHEP Ipc: A61K 31/216 20060101AFI20190312BHEP Ipc: A61K 31/517 20060101ALI20190312BHEP Ipc: A61K 31/4439 20060101ALI20190312BHEP Ipc: A61K 31/4178 20060101ALI20190312BHEP Ipc: A61K 9/70 20060101ALI20190312BHEP Ipc: A61P 25/24 20060101ALI20190312BHEP Ipc: A61K 31/166 20060101ALI20190312BHEP Ipc: A61P 25/28 20060101ALI20190312BHEP Ipc: A61P 25/18 20060101ALI20190312BHEP Ipc: A61P 25/00 20060101ALI20190312BHEP Ipc: A61P 25/14 20060101ALI20190312BHEP Ipc: A61K 31/439 20060101ALI20190312BHEP Ipc: A61P 43/00 20060101ALI20190312BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20200623 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230331 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20230310 |